# A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.

> **NCT01415102** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Phase 1
- Single Dose
- Safety
- Toleration
- Pharmacokinetics

## Interventions

- **DRUG:** PF-05212372
- **DRUG:** PF-05212372
- **DRUG:** PF-05212372
- **DRUG:** PF-05212372
- **DRUG:** Placebo
- **DRUG:** PF-05212372
- **DRUG:** PF-05212372
- **DRUG:** PF-05212372
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01415102
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415102, "A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01415102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*